Published in Cancer on February 01, 2010
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist (2012) 1.33
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int (2012) 1.12
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A (2016) 0.85
Unusual early-stage pancreatic sarcomatoid carcinoma. World J Gastroenterol (2013) 0.84
PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma? J Clin Pathol (2014) 0.79
Paired specimens: an opportunity to answer some important questions. Cancer (2010) 0.79
Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. J Cancer Res Clin Oncol (2013) 0.78
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol (2015) 0.75
Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res (2015) 0.75
The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol (2016) 0.75
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 3.85
Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol (2001) 2.91
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer (2004) 1.53
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol (2007) 1.51
Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol (1999) 1.36
Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer (1987) 1.33
Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology (1999) 1.22
Sarcomatoid renal cell carcinoma: the chromophobe connection. Am J Surg Pathol (1997) 1.18
Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer (2005) 1.16
Sarcomatoid renal carcinoma. J Urol (1983) 1.09
Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. Arch Pathol Lab Med (1993) 1.06
Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol (2007) 1.04
Sarcomatoid carcinoma of the kidney. J Urol (1987) 1.04
Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. J Pathol (1998) 0.99
Cell proliferative activity and expression of cell-cell adhesion factors (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) in sarcomatoid renal cell carcinoma. J Surg Oncol (2001) 0.97
Chromosome changes in sarcomatoid renal carcinomas are different from those in renal cell carcinomas. Cancer Genet Cytogenet (2002) 0.89
Osteogenic and sarcomatoid differentiation of a renal cell carcinoma. Cancer (1985) 0.83
Sarcomatoid renal cell carcinoma. A study of its proliferative activity. Cancer (1993) 0.82
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell (2005) 7.29
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
A polymer tandem solar cell with 10.6% power conversion efficiency. Nat Commun (2013) 4.48
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/- and Ldlr-/- mice lacking CHOP. Cell Metab (2009) 3.51
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev (2010) 3.49
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res (2003) 3.30
Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell (2012) 3.30
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
For the bright future-bulk heterojunction polymer solar cells with power conversion efficiency of 7.4%. Adv Mater (2010) 3.24
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology (2004) 3.14
Osteopontin expression correlates with melanoma invasion. J Invest Dermatol (2005) 3.13
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest (2009) 2.82
Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain (2011) 2.80
Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res (2011) 2.73
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature (2005) 2.63
Four novel frameworks built by imidazole-based dicarboxylate ligands: hydro(solvo)thermal synthesis, crystal structures, and properties. Inorg Chem (2010) 2.60
End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV. JACC Heart Fail (2020) 2.57
A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med (2012) 2.53
Cep120 and TACCs control interkinetic nuclear migration and the neural progenitor pool. Neuron (2007) 2.53
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol (2009) 2.37
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Planar heterojunction perovskite solar cells via vapor-assisted solution process. J Am Chem Soc (2013) 2.32
Empirical likelihood analysis of the Buckley-James estimator. J Multivar Anal (2008) 2.28
Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet (2011) 2.27
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas (2008) 2.24
APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol (2003) 2.21
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol (2006) 2.09
Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis (2008) 2.09
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res (2011) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med (2003) 2.02
Suicide risk among perinatal women who report thoughts of self-harm on depression screens. Obstet Gynecol (2015) 2.01
Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol (2005) 2.01
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist (2009) 1.99
Activation of remote meta-C-H bonds assisted by an end-on template. Nature (2012) 1.96
Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet (2013) 1.95
Color Doppler sonography reliably identifies testicular torsion in boys. Urology (2009) 1.95
Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci (2010) 1.93
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
DAG lipase activity is necessary for TRP channel regulation in Drosophila photoreceptors. Neuron (2008) 1.86
Application of NIR spectroscopy for firmness evaluation of peaches. J Zhejiang Univ Sci B (2008) 1.86
The rice HIGH-TILLERING DWARF1 encoding an ortholog of Arabidopsis MAX3 is required for negative regulation of the outgrowth of axillary buds. Plant J (2006) 1.85
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84
Mesenchymal stem cells in immunoregulation. Immunol Cell Biol (2006) 1.82
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun (2011) 1.80
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
An approach to joint analysis of longitudinal measurements and competing risks failure time data. Stat Med (2007) 1.78
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Interaction of Arabidopsis DET1 with CCA1 and LHY in mediating transcriptional repression in the plant circadian clock. Mol Cell (2011) 1.75
Doublecortin-like kinase controls neurogenesis by regulating mitotic spindles and M phase progression. Neuron (2006) 1.74
PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care (2010) 1.73
Tumour necrosis factor-alpha affects blood-brain barrier permeability and tight junction-associated occludin in acute liver failure. Liver Int (2010) 1.72
Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology (2013) 1.71
Direct, nonoxidative conversion of methane to ethylene, aromatics, and hydrogen. Science (2014) 1.71
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69